Product Description
CBP233 is an IL-33 mAb being developed by Connect Biopharma for Type 2 Inflammatory Diseases. (Sourced from: https://www.connectbiopharm.com/pipeline2/)
Mechanisms of Action: IL33 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Connect Biopharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Systemic Inflammation
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|